# A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents

> **NCT04535453** · PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 635 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.COV2.S
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04535453
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-28
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-09
- **Target enrollment:** 635 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535453, "A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04535453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*